Bharat Biotech presents Covaxin phase 3 trials data; Expert panel may have a meeting

The subject expert committee of the central drugs standards control organisation (CDSCO) will be reviewing the data of Covaxin’s phase 3 clinical trials cinducted by Bharat Biotech as the company submitted it to Drugs Controller General of India (DCGI) over the weekend, according to sources aware about the development.

An official, who wants to be anonymous said, “The required data has been submitted, and the meeting of the expert panel is likely to take place today.”

Bharat Biotech has scheduled for a pre-submission meeting with the World Health Organization (WHO’s) representatives on June 23, Wednesday for their Covid-19 vaccine, Covaxin to be placed under emergency use listig (EUL).

Covaxin has proven to have 78 % efficacy in the final interim phase 3 analysis.

In March, the first interim analysis result was released according to 43 cases, from which 36 were observed with the placebo group comparing to 7 cases under BBV152 group, which leads to vaccine efficacy estimated to be 80.6%.

In April, the second interim analysis was presented according to over 87 symptomatic cases of Covid-19, and revealed that efficacy against severe Covid-19 disease was 100 %, which would reduce the hospitalizations.

In the phase 3 study, 25,800 participants from 18-98 yeats of age group were enrolled, and the analysis was carried out 14 days after the second dose.

• Statewide Transport Workers’ Strike from Dec 31: Disruption in Bus Services Likely
• Mandya Kannada Sahitya Sammelana: Traffic Diversion on Bengaluru-Mysuru Expressway
• Ravichandran Ashwin Announces Sudden Retirement from International Cricket
• Free Cancer Vaccine Distribution in Russia from 2025: A Remarkable Medical Breakthrough
• Train Services Delayed Between Bengaluru-Mysuru: Introduction of New Train Numbers